Talecris is proudly building upon a 60-year legacy of innovation and a commitment to the patients who rely on its therapeutic products to manage their conditions.
Today, Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that specializes in therapies derived from human plasma. Talecris is a leader in pathogen safety, and our commitment to safety can be seen in every step of our unique manufacturing processes. From screening potential plasma donors at our national network of plasma-collection centers through the virus inactivation and removal steps in the manufacture of the final product, Talecris is committed to safety, one step at a time.
The Talecris commitment extends to the patient communities who rely on our products. Talecris supports the World Federation of Hemophilia and the National Hemophilia Foundation in their efforts to educate patients and increase awareness. We also fund grant programs, research, and continuing education programs for healthcare professionals and scientists to further advance the standards of care for patients.
Talecris extends this same commitment to the communities in which we have a corporate presence because these are home to our most valuable resources: employees and their families. As part of that commitment, the Talecris Biotherapeutics Giving Program supports many local community programs.
Our Mission:
To provide innovative biotherapeutics that help patients manage their conditions while creating value for patients, employees, communities, and investors.
Our Vision:
To be the recognized global leader in developing and providing vital protein therapeutics.
© 2009–2011 Talecris Biotherapeutics, Inc.